| P50 | author | Elisa Avitabile | Q124273094 |
| | Gabriella Campadelli-Fiume | Q21062117 |
| | Costanza Casiraghi | Q56922647 |
| | Valerio Leoni | Q57015112 |
| | Valentina Gatta | Q57123026 |
| | Tatiana Gianni | Q57126184 |
| | Biljana Petrovic | Q57314115 |
| P2860 | cites work | Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma | Q84834335 |
| | Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma | Q84906858 |
| | Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor | Q24322090 |
| | The ectodomain of a novel member of the immunoglobulin subfamily related to the poliovirus receptor has the attributes of a bona fide receptor for herpes simplex virus types 1 and 2 in human cells | Q24523691 |
| | New viruses for cancer therapy: meeting clinical needs | Q24567699 |
| | Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours--evaluation of a potentially effective clinical therapy | Q24679781 |
| | From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer | Q26822694 |
| | Herpes simplex virus glycoprotein D bound to the human receptor HveA | Q27634177 |
| | Crystal structure of the conserved herpesvirus fusion regulator complex gH–gL | Q27663096 |
| | Structure of a core fragment of glycoprotein H from pseudorabies virus in complex with antibody | Q27666356 |
| | Structure of Herpes Simplex Virus Glycoprotein D Bound to the Human Receptor Nectin-1 | Q27674775 |
| | A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry | Q28145858 |
| | Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family | Q28295196 |
| | Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM | Q33712977 |
| | A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer | Q33713249 |
| | Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. | Q33786002 |
| | The pro-fusion domain of herpes simplex virus glycoprotein D (gD) interacts with the gD N terminus and is displaced by soluble forms of viral receptors | Q33879094 |
| | Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial | Q33905053 |
| | ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties | Q34178661 |
| | Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas | Q34297434 |
| | Structure of unliganded HSV gD reveals a mechanism for receptor-mediated activation of virus entry. | Q34324896 |
| | Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction | Q34381483 |
| | Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins | Q34463480 |
| | Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma | Q34478015 |
| | Carrier cell-based delivery of replication-competent HSV-1 mutants enhances antitumor effect for ovarian cancer | Q34512446 |
| | Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. | Q34574879 |
| | A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. | Q34583808 |
| | Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptor | Q34600345 |
| | A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors | Q34648103 |
| | Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma | Q34794313 |
| | Structure-function analysis of herpes simplex virus type 1 gD and gH-gL: clues from gDgH chimeras | Q35020198 |
| | Directing systemic oncolytic viral delivery to tumors via carrier cells | Q35029126 |
| | Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors | Q35051285 |
| | Molecular gymnastics at the herpesvirus surface | Q35102490 |
| | Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV | Q35591421 |
| | Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus | Q35596563 |
| | Fusing structure and function: a structural view of the herpesvirus entry machinery | Q35622700 |
| | The Engineering of a Novel Ligand in gH Confers to HSV an Expanded Tropism Independent of gD Activation by Its Receptors | Q35638350 |
| | Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma | Q45413172 |
| | Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice | Q45728532 |
| | Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. | Q45732876 |
| | Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. | Q45748695 |
| | In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity | Q45756276 |
| | Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant | Q45854779 |
| | Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses | Q46972161 |
| | Vitamin D3-inducible mesenchymal stem cell-based delivery of conditionally replicating adenoviruses effectively targets renal cell carcinoma and inhibits tumor growth | Q64379255 |
| | Rescue and propagation of fully retargeted oncolytic measles viruses | Q81348398 |
| | Separation of receptor-binding and profusogenic domains of glycoprotein D of herpes simplex virus 1 into distinct interacting proteins | Q35676817 |
| | Dissociation of HSV gL from gH by αvβ6- or αvβ8-integrin promotes gH activation and virus entry | Q35895648 |
| | Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma | Q35939421 |
| | Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children. | Q36109704 |
| | Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases | Q36544212 |
| | Regulation of herpes simplex virus gB-induced cell-cell fusion by mutant forms of gH/gL in the absence of gD and cellular receptors | Q36647949 |
| | Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus | Q36659325 |
| | The multipartite system that mediates entry of herpes simplex virus into the cell | Q36851086 |
| | Clinical Significance of HER-2 Splice Variants in Breast Cancer Progression and Drug Resistance. | Q37019041 |
| | Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth | Q37115384 |
| | Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice | Q37132189 |
| | Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded | Q37191007 |
| | Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells | Q37198935 |
| | The utility of cells as vehicles for oncolytic virus therapies. | Q37236085 |
| | Cell carriers for oncolytic viruses: Fed Ex for cancer therapy | Q37582184 |
| | Viral and cellular contributions to herpes simplex virus entry into the cell | Q37996244 |
| | Oncolytic virotherapy | Q38025263 |
| | From virotherapy to oncolytic immunotherapy: where are we now? | Q38539862 |
| | Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells | Q38918317 |
| | DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety | Q39199726 |
| | Oncolytic herpes simplex virus treatment of metastatic breast cancer | Q39438675 |
| | Glycoprotein gL-independent infectivity of pseudorabies virus is mediated by a gD-gH fusion protein | Q39549912 |
| | Development of an oncolytic herpes simplex virus using a tumor-specific HIF-responsive promoter | Q39646942 |
| | Transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1 for targeting prostate tumors | Q39735950 |
| | Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. | Q39852211 |
| | Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. | Q39953338 |
| | PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting | Q40233745 |
| | Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence. | Q40373406 |
| | The herpes simplex virus JMP mutant enters receptor-negative J cells through a novel pathway independent of the known receptors nectin1, HveA, and nectin2. | Q40567844 |
| | Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy. | Q42218017 |
| | Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity | Q42248592 |
| | Analysis of a membrane interacting region of herpes simplex virus type 1 glycoprotein H. | Q42736704 |
| | Novel tumour-specific promoters for transcriptional targeting of hepatocellular carcinoma by herpes simplex virus vectors | Q42793390 |
| | Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer | Q43537822 |
| | Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture | Q44460699 |
| | Intralesional injection of herpes simplex virus 1716 in metastatic melanoma | Q44718611 |
| | Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver | Q45289528 |
| | A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer | Q45371067 |
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | viral structural protein | Q7933613 |
| | Erb-b2 receptor tyrosine kinase 2 | Q415271 |
| | Simplexvirus | Q1509095 |
| | oncolytic virus | Q1560099 |
| | viral tropism | Q59717570 |
| | virus receptors | Q66053321 |
| P304 | page(s) | 63 | |
| P577 | publication date | 2016-02-26 | |
| | 2016-03-01 | |
| P1433 | published in | Viruses | Q7935305 |
| P1476 | title | Retargeting Strategies for Oncolytic Herpes Simplex Viruses | |
| P478 | volume | 8 | |